Recombinant human erythropoietin alters gene expression and stimulates proliferation of MCF-7 breast cancer cells

1. Moritz KM, Lim GB, Wintour EM. Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol 1997; 273: R1829-44.10.1152/ajpregu.1997.273.6.R1829Search in Google Scholar

2. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67: 39-61.10.1016/j.critrevonc.2008.03.006Search in Google Scholar

3. Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992; 210: 649-63.10.1111/j.1432-1033.1992.tb17466.xSearch in Google Scholar

4. Dessypris EN, Krantz SB. Effect of pure erythropoietin on DNA-synthesis by human marrow day 15 erythroid burst forming units in short-term liquid culture. Br J Haematol 1984; 56: 295-306.10.1111/j.1365-2141.1984.tb03957.xSearch in Google Scholar

5. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996; 88: 1576-82.10.1182/blood.V88.5.1576.1576Search in Google Scholar

6. Elliott S, Sinclair AM. The effect of erythropoietin on normal and neoplastic cells. Biologics 2012; 6: 163-89.Search in Google Scholar

7. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000; 58: 647-57.10.1046/j.1523-1755.2000.00211.xSearch in Google Scholar

8. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu XW. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005; 166: 823-30.10.1016/S0002-9440(10)62303-6Search in Google Scholar

9. Selzer E, Wacheck V, Kodym R, Schlagbauer-Wadl H, Schlegel W, Pehamberger H, et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000; 10: 421-6.10.1097/00008390-200010000-0000311095402Search in Google Scholar

10. Ludwig H. rHuEPO and treatment outcomes: the preclinical experience. Oncologist 2004; 9 (Suppl 5): 48-54.10.1634/theoncologist.9-90005-4815591422Search in Google Scholar

11. Nakamura Y, Komatsu N, Nakauchi H. A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science 1992; 257: 1138-41.10.1126/science.257.5073.11381324524Search in Google Scholar

12. Todokoro K, Kuramochi S, Nagasawa T, Abe T, Ikawa Y. Isolation of a cDNA encoding a potential soluble receptor for human erythropoietin. Gene 1991; 106: 283-4.10.1016/0378-1119(91)90213-USearch in Google Scholar

13. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-40.10.1073/pnas.95.8.4635225429539790Search in Google Scholar

14. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007; 110: 477-88.10.1002/cncr.2283217582631Search in Google Scholar

15. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002; 82: 911-8.10.1097/01.LAB.0000020415.72863.4012118093Search in Google Scholar

16. Hevir N, Trost N, Debeljak N, Rizner TL. Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines. Chem Biol Interact 2011; 191: 206-16.10.1016/j.cbi.2010.12.01321182832Search in Google Scholar

17. Mounier CM, Wendum D, Greenspan E, Flejou JF, Rosenberg DW, Lambeau G. Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer 2008; 98: 587-95.10.1038/sj.bjc.6604184224314918212756Search in Google Scholar

18. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.10.1186/gb-2002-3-7-research003412623912184808Search in Google Scholar

19. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative realtime PCR experiments. Clin Chem 2009; 55: 611-22.10.1373/clinchem.2008.11279719246619Search in Google Scholar

20. Smyth GK. Limma: linear models for microarray data. In: Robert Gentleman VJC, Wolfgang Huber, Rafael A. Irizarry, Sandrine Dudoit editor. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005. p.397-420.10.1007/0-387-29362-0_23Search in Google Scholar

21. (2008) RDCT. R: A language and environment for statistical computing. Vienna: R Fundation for Statistical Computing; 2011.Search in Google Scholar

22. Benjamini Y. Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. R Stat Soc Series B Stat Methodol 1995; 57: 289-300.10.1111/j.2517-6161.1995.tb02031.xSearch in Google Scholar

23. Noguchi CT, Asavaritikrai P, Teng R, Jia Y. Role of erythropoietin in the brain. Crit Rev Oncol Hematol 2007; 64: 159-71.10.1016/j.critrevonc.2007.03.001Search in Google Scholar

24. Nishiya D, Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S, et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006; 101: 31-9.10.1254/jphs.FP0050966Search in Google Scholar

25. Szenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. Biochim Biophys Acta 2010; 1806: 82-95.Search in Google Scholar

26. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010; 18: 423-35.10.1016/j.ccr.2010.10.025Search in Google Scholar

27. Trost N, Hevir N, Rizner TL, Debeljak N. Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines. Int J Mol Med 2013; 31: 717-25.10.3892/ijmm.2013.1231Search in Google Scholar

28. Lu C, Shen Q, DuPre E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth. Oncogene 2005; 24: 6516-24.10.1038/sj.onc.1208905Search in Google Scholar

29. Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 2004; 23: 981-90.10.1038/sj.onc.1207294Search in Google Scholar

30. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Ando S, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006; 20: 631-46.10.1210/me.2005-0280Search in Google Scholar

31. Trost N, Juvan P, Sersa G, Debeljak N. Contrasting effect of recombinant human erythropoietin on breast cancer cell response to cisplatin induced cytotoxicity. Radiol Oncol 2012; 46: 213-25.10.2478/v10019-012-0037-8Search in Google Scholar

32. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003; 307: 999-1007.10.1016/S0006-291X(03)01303-2Search in Google Scholar

33. Singh S, Dev A, Verma R, Pradeep A, Sathyanarayana P, Green JM, et al. Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation. PLoS One 2012; 7: e38530. 10.1371/journal.pone.0038530339664122808010Search in Google Scholar